Results 181 to 190 of about 18,508 (192)

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Lancet, The, 2017
Adriano Lazzarin, Chloe Orkin, Daniel Podzamczer   +2 more
exaly  

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

New England Journal of Medicine, 2019
Willem Venter, Michelle A Moorhouse, Simiso Sokhela   +2 more
exaly  

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

New England Journal of Medicine, 2013
Sharon L Walmsley, Felix Gutierrez, Laurent Hocqueloux   +2 more
exaly  

Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

New England Journal of Medicine, 2018
Rebecca Zash, Roger L Shapiro
exaly  

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States

New England Journal of Medicine, 2022
exaly  

Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

New England Journal of Medicine, 2019
Bruno Spire, Sandrine Leroy, Sylvie Boyer   +2 more
exaly  

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R

New England Journal of Medicine, 2019
Nadine Lübke
exaly  

Dolutegravir

Reactions Weekly, 2016
openaire   +1 more source

Antiretroviral therapy: dolutegravir sets SAIL(ING)

Lancet, The, 2013
Basil J Donovan
exaly  

Dolutegravir for HIV: a lesson in pregnancy safety research

Lancet, The, 2018
exaly